We’re determined to change the standard of care for people who are affected by rare blood disorders, and to find answers for people living with diseases for which no treatment is available. To do that, we’re building on a legacy of innovation that stems from the development of the first extended half-life clotting factors for treating hemophilia A and B, branching out to the first approved treatment for acquired thrombotic thrombocytopenic purpura (aTTP), and cutting-edge R&D in cold agglutinin disease.
Sincerely Pharmaceutical Tech
Regards,
Client Success Team (CRM),
Please fill the all required fields....!!
Sincerely Packaging Labelling
